Presentation is loading. Please wait.

Presentation is loading. Please wait.

Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD 

Published byÊÊΔιομήδης Κουρμούλης Modified over 5 years ago

Similar presentations

Presentation on theme: "Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD "— Presentation transcript:

1 The mTOR Pathway in Lung Cancer and Implications for Therapy and Biomarker Analysis 
Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 6, Pages (June 2012) DOI: /JTO.0b013e bd Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 mTOR-signaling network. Activated growth factor receptors trigger activation of the PI3K/Akt pathways and the Ras/MEK/Erk pathway. Activated Akt leads to increased mTOR activity through signaling by means of the TSC1/2 complex. mTOR then phosphorylates S6K1 and 4E-BP1, resulting in increased gene transcription, cell growth, and cell proliferation. PI3-K, phosphatidylinositol 3-kinase; AMPK, adenosine mono-phosphate-activated protein kinase; LKB1, liver kinase B1; PTEN, phosphatase and tensin homologue; STRAD, Ste20-like adaptor protein; TSC, tuberous sclerosis complex; EGFR, epidermal growth factor receptor; mTOR, mammalian target of rapamycin; m, signaling proteins frequently mutated in lung cancer; bm, potential as biomarker; Ras, ras2 Kirsten rat sarcoma viral oncogene homolog; MEK, MAPK/ERK kinase; Erk, extracellular signal-regulated kinase. Journal of Thoracic Oncology 2012 7, DOI: ( /JTO.0b013e bd) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD "

Similar presentations

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.
Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy  Flavia.

Inducible EGFR T790M-Mediated Gefitinib Resistance in Non-small Cell Lung Cancer Cells Does Not Modulate Sensitivity to PI103 Provoked Autophagy  Flavia.
Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 

Frances A Shepherd, MD, Rafael Rosell, MD  Journal of Thoracic Oncology 
Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 

Silvestri Gerard A. , MD, FCCP, Rivera M. Patricia , MD, FCCP  CHEST 
Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
Advances in Molecular Biology of Lung Disease

Advances in Molecular Biology of Lung Disease
by Rogelio Zamilpa, and Merry L. Lindsey

by Rogelio Zamilpa, and Merry L. Lindsey
Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M

Akihito Muto, MD, PhD, Tamara N. Fitzgerald, MD, PhD, Jose M
Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis

Activation of Oncogenic Pathways in Idiopathic Pulmonary Fibrosis
LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT  Jacob M. Kaufman,

LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT  Jacob M. Kaufman,
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Lu Chen, PhD, Brienne E. Engel, PhD, Eric A. Welsh, PhD, Sean J

Lu Chen, PhD, Brienne E. Engel, PhD, Eric A. Welsh, PhD, Sean J
Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,

Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era  Joon H. Uhm, MD, Alyx B. Porter,
cMET Exon 14 Skipping: From the Structure to the Clinic

cMET Exon 14 Skipping: From the Structure to the Clinic
Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E

Daniel Morgensztern, MD, Meghan J. Campo, MD, Suzanne E
Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose  Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.
Ground glass opacities: Imaging, pathology, and gene mutations

Ground glass opacities: Imaging, pathology, and gene mutations
Kinase inhibitors: Vice becomes virtue

Kinase inhibitors: Vice becomes virtue
Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3- Kinase/AKT/Mammalian Target of Rapamycin Pathway  Gozde Akgumus, Fengqi.

Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3- Kinase/AKT/Mammalian Target of Rapamycin Pathway  Gozde Akgumus, Fengqi.
Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

Targeting ROS1 with Anaplastic Lymphoma Kinase Inhibitors: A Promising Therapeutic Strategy for a Newly Defined Molecular Subset of Non–Small-Cell Lung.

Similar presentations

Ads by Google